Nanocarrier-Enabled siRNA Therapy for Pulmonary Fibrosis: Pharmacological Rationale, Delivery Barriers, and Translational Opportunities
International Journal of Nanomedicine · 2026
DOI: 10.2147/ijn.s640244 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Nanomedicine, 2026. Verfasst von Zhao-Qi Lv und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, Jilin, 130041, People's Republic of China. Hauptthemen laut MEDLINE: RNA, Small Interfering, Pulmonary Fibrosis, Nanoparticles, Nanoparticle Drug Delivery System. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun, Jilin, 130041, People's Republic of China.
Zitieren
APA
Lv, Z. Q., Wang, K., Di, X., & Cong, S. (2026). Nanocarrier-Enabled siRNA Therapy for Pulmonary Fibrosis: Pharmacological Rationale, Delivery Barriers, and Translational Opportunities. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s640244
Vancouver
Lv ZQ, Wang K, Di X, Cong S. Nanocarrier-Enabled siRNA Therapy for Pulmonary Fibrosis: Pharmacological Rationale, Delivery Barriers, and Translational Opportunities. International Journal of Nanomedicine. 2026. doi:10.2147/ijn.s640244
BibTeX
@article{Lv2026,
author = {Lv, Zhao-Qi and Wang, Ke and Di, Xin and Cong, Shan},
title = {Nanocarrier-Enabled siRNA Therapy for Pulmonary Fibrosis: Pharmacological Rationale, Delivery Barriers, and Translational Opportunities},
journal = {International Journal of Nanomedicine},
year = {2026},
doi = {10.2147/ijn.s640244}
}
EUVIMED